Numinus Wellness Sells Off Shares In Alto Neuroscience Ahead Of IPO

Numinus Wellness (TSX: NUMI) is reporting this morning that it has sold its interest in Alto Neuroscience, a clinical-stage biopharma company that filed for its initial public offering earlier this week.

Alto’s current biotech pipeline is centered on tackling depression, with three clinical-stage programs currently underway, including one for its lead drug, ALTO-100. The drug is in a phase 2b trial, with results expected in the second half of the year.

The company is currently expected to raise between $93.8 and $107.2 million in gross proceeds from its go public, selling 6.7 million shares in a range of $14 to $16 a piece.

Numinous meanwhile held 1,000 non-voting participation shares of Alto within a special purpose vehicle, which Novamind, whom Numinus previously acquired, purchased at a price of $1.22 million. It is unclear at what ratio these shares would have converted into common stock. The fair value of the holdings were reported as being $1.6 million as of November 30, 2023.

“As our core strategy is to build the critical infrastructure that addresses the growing need for effective mental health treatments, the proceeds from the sale of this non-core asset will provide additional financial liquidity and flexibility,” commented Payton Nyquvest on the sale.

Total proceeds from the sale by Numinus were not disclosed.

Numinus Wellness last traded at $0.14 on the TSX.


Information for this briefing was found via Numinus Wellness. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Leave a Reply

Video Articles

Endeavour Mining Q1 Earnings: Cash Flow Is King

G Mining Oko West Feasibility: Move Fast, Break.. Nothing?

New Gold Q1 Earnings: What’s Behind The Market’s Surprising Reaction?

Recommended

Giant Mining Encounters Native Copper As Hole MHB-34 Hits 563 Metres Depth

Verses Hits Commercialization Stage With Genius AI Platform

Related News

Numinus Wellness Walks From Acquisition Of MedBright AI

Numinus Wellness (TSX: NUMI) has walked away from a plan to add artificial intelligence assets...

Monday, August 12, 2024, 10:08:35 AM

Numinus Wellness: Eight Capital Initiates With $1.10 Price Target

Last week, Eight Capital launched coverage on a basket of psychedelic companies. This comes after...

Monday, September 20, 2021, 02:41:00 PM

Numinus Wellness Halts Stock For Trading Day To Announce $17 Million Financing Closing

After halting trading in its equity all day, Numinus Wellness (TSXV: NUMI) this evening finally...

Tuesday, December 29, 2020, 04:49:21 PM

Numinus Wellness To Acquire Novamind In All Stock Transaction At $0.44 Per Share

Consolidation within the psychedelics space is getting underway, with the announcement this morning that Numinus...

Tuesday, April 12, 2022, 07:56:51 AM

Numinus Wellness To Acquire MedBright AI In Bid To Add Artificial Intelligence To Portfolio

Numinus Wellness (TSX: NUMI) is set to get into the artificial intelligence business. The firm...

Thursday, June 20, 2024, 09:41:47 AM